MYELOPEROXIDASE POLYMORPHISM ON ENDOTHELIAL FUNCTION AND VASCULAR COMPLIANCE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是确定一种名为“髓过氧化物酶”的基因的自然变异是否在血管功能异常中起作用。众所周知，这种血管的异常会影响血压，还会导致心脏问题。这是对一种名为髓过氧化物酶(MPO)基因的特定基因的研究，因为医学研究表明，这种基因的某种变化在心脏病患者中更常见。这是一项对MPO基因有这种变异的人和没有这种变异的人的血管功能的比较研究。这种比较将使用一种名为氨苯砜的药物进行。氨苯松能阻断髓过氧化物酶的作用，这种酶是由MPO基因产生的。氨苯砜被FDA批准用于某些皮肤病的治疗，但在本研究中被认为是调查性的。 受试者将1)年龄在18岁至45岁之间，没有已知的心脏病风险因素，或2)有心脏病的风险因素，如高血压、高胆固醇或20年来每天吸烟超过一包，并且是a)年龄45-69岁的男性，或b)绝经后女性，年龄不到69岁。受试者将被随机分配接受氨苯砜或安慰剂。 这项研究的假设是：1)MPO GG基因型与血管功能受损有关，2)GG基因型受试者的血管功能障碍可以通过氨苯酮抑制MPO而得到改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine if a natural variation in a gene called "myeloperoxidase" plays a role in the abnormal functioning of blood vessels. It is known that this abnormality of blood vessels affects blood pressure and also leads to heart problems. This is a study of a particular gene, called the myeloperoxidase (MPO) gene, since medical studies have suggested that a certain change in this gene is seen more often in patients with heart disease. This is a study of blood vessel function in people having this variation in the MPO gene compared to a group that does not have the variation. This comparison will be made using a medication called dapsone. Dapsone is known to block the effect of an enzyme called "myeloperoxidase", produced by the MPO gene. Dapsone is approved by the FDA for treatment of certain skin conditions but is considered investigational for the purpose of this study. Subjects will 1) be between 18 and 45 years old and have no known risk factors for heart disaease or 2) have risk factors for heart disease such as high blood pressure, high cholesterol or have smoked more than 1 pack per day for 20 years and are a) male, aged 45-69 years, or b) postmenopausal women, less than 69 years old. Subjects will be randomly assigned to receive dapsone or placebo. The hypotheses of the study are: 1) The MPO GG genotype is associated with impaired vascular function, and 2) vascular dysfunction in subjects with GG genotype is improved by inhibiting MPO with dapsone therapy.